Axalbion SA
Chief Scientific Officer, Director & Co-founder
Scientific leadership of a chronic cough treatment program, from preclinical development through Phase 2 clinical studies.
Responsibilities & highlights
- Directed a clinical program comprising one two-part Phase 1 study and two Phase 2 studies, enrolling 140 participants overall.
- Designed and supervised 40+ nonclinical studies in pharmacology, pharmacokinetics and toxicology.
- Coordinated clinical feasibility, site and vendor selection, CMC, clinical supply, and ethics and regulatory submissions.
- Drafted clinical protocols, Investigator’s Brochures, risk assessments and Clinical Study Reports.
- Supported $20M+ in fundraising through investor materials, due diligence and discussions with investors and pharmaceutical companies.
- Wrote a successful CHF 500k Innosuisse grant with the University Hospital of Zurich.
- Managed the patent portfolio and co-invented a patent family, including PCT/EP2020/066065.
Lausanne, Switzerland